# EOS Technology Investment Syndicate

> EOS Technology Investment Syndicate is a VC fund backing Biotechnology. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 6
- Last investment: Sep 2024
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://www.eos-tech-investors.com/

EOS Technology Investment Syndicate is a VC fund focused on Biotechnology and Health Care. EOS Technology Investment Syndicate

## Contacts

5 contacts available for EOS Technology Investment Syndicate. Shizune tracks 1 team members at EOS Technology Investment Syndicate. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eos-technology-investment-syndicate?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Health Care | 1 | 17% |
| Life Science | 1 | 17% |
| Therapeutics | 1 | 17% |
| 3D Technology | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Series A | 1 | 17% |
| Funding Round | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kevin Grainger | Chairman & Gatekeeper | 2 | https://shizune.co/investors/profile/kevin-grainger |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ILC Therapeutics | ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis. | $3.3M | Venture - Series Unknown | Sep 11, 2024 |  |
| ILC Therapeutics | ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis. | $4.8M | Venture - Series Unknown | Sep 06, 2021 |  |
| Chromacity | Chromacity Lasers is a spin-out from Heriot-Watt University, one of the UK’s leading technical universities with a focus on photonics. Their founding team has over 40 years’ experience in ultrafast lasers and fiber lasers. They have developed wavelength tunable femtosecond lasers from the ultraviolet (400 nm) to the mid-infrared (> 6 µm) forindustrial and scientific applications in fluorescence microscopy, gas spectroscopy, laser material processing and semiconductor engineering.Robust, patent-pending femtosecond fiber-laser technology underpins every product, delivering reliable, turn-key performance. But they don’t stop there: their embedded web server provides a uniquely simple control interface, allowing wireless operation from any laptop, tablet or smartphone.Their focus is on manufacturing femtosecond lasers for life-sciences applications. In parallel with these core products, they work with systems manufacturers to provide custom OEM femtosecond and picosecond lasers optimized for specific applications in engineering and materials processing. They can provide combinations of pulse repetition rate, energy and wavelength not available from any other manufacturers. | $1.7M | Seed | Aug 11, 2021 |  |
| ENOUGH | ENOUGH is a technology spin-out company from the University of Strathclyde established to develop and commercialise novel patented technology which transforms the production economics for the meat-free food product mycoprotein by integrating the production within existing bio-refinery operations producing bio-ethanol and animal feed (DDGS). Thisgives integrated fermentation production of Food, Fuel and Feed. ​ | $8.1M | Series A | Apr 04, 2018 |  |
| ENOUGH | ENOUGH is a technology spin-out company from the University of Strathclyde established to develop and commercialise novel patented technology which transforms the production economics for the meat-free food product mycoprotein by integrating the production within existing bio-refinery operations producing bio-ethanol and animal feed (DDGS). Thisgives integrated fermentation production of Food, Fuel and Feed. ​ | $604K | Seed | Jul 16, 2017 |  |
| Alfacyte | Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy. | $327K |  | Jan 04, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 3 deals together
- [Scottish Investment Bank](https://shizune.co/investors/profile/scottish-investment-bank) — VC Fund, 3 deals together
- [Kelvin Capital](https://shizune.co/investors/profile/kelvin-capital) — VC Fund, 2 deals together
- [University of Strathclyde](https://shizune.co/investors/profile/university-of-strathclyde) — VC Fund, 2 deals together
- [EOS technologies](https://shizune.co/investors/profile/eos-technologies) — VC Fund, 1 deal together
- [ESM Investment Ltd](https://shizune.co/investors/profile/esm-investment-ltd) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does EOS Technology Investment Syndicate invest in?

EOS Technology Investment Syndicate invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact EOS Technology Investment Syndicate?

Public channels for EOS Technology Investment Syndicate include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at EOS Technology Investment Syndicate?

The team at EOS Technology Investment Syndicate includes Kevin Grainger (Chairman & Gatekeeper). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co